Determination of the Nail Psoriasis Severity Index improvement rate standards for nail psoriasis treatment in a phase <scp>IV</scp> clinical trial of ustekinumab: the <scp>MARCOPOLO</scp> study

Youn, Sang Woong; Kim, B.R.; Cho, Sang Wan; Seo, Su Jean; Lee, E.S.; Roh, Joo Young; Choi, Gwang Seong; Lee, M.G.

doi:10.1111/jdv.14083

Cited by 6 publications

(3 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Despite its limitations, “PASI 75,” which signifies a 75% improvement in PASI score from before treatment to after treatment, is generally accepted as a common criterion for evaluating symptom improvement in psoriasis. However, NAPSI does not have specific target improvement rates, such as PASI 75 or PASI 90 17 .…”

Section: Application Of Nail Psoriasis Severity Assessment Tools For ...mentioning

confidence: 99%

“…Therefore, it is necessary to lower the standards for setting improvement rates instead of relying on NAPSI 50 and NAPSI 75 as reference points. In a previous study that examined the effect of ustekinumab on nail psoriasis 17 , the NAPSI improvement rates similar to the level of improvement for skin psoriasis, such as PASI 75 and PASI 90, were suggested as NAPSI 40 and NAPSI 70.…”

Section: Application Of Nail Psoriasis Severity Assessment Tools For ...mentioning

confidence: 99%

See 1 more Smart Citation

Nail Psoriasis: Clinical Features and Severity Assessment

Youn

2024

Ann Dermatol

View full text Add to dashboard Cite

The nail is an important characteristic in the context of psoriasis. Nail psoriasis exhibits several clinical manifestations. Since the development of the Nail Psoriasis Severity Index (NAPSI) score assessment tool for evaluating the severity of nail psoriasis, nail matrix symptoms such as pitting, leukonychia, crumbling, and red spots have been observed in the lunula. Nail bed symptoms include onycholysis, subungual hyperkeratosis, oil spots, and splinter hemorrhage. However, Beau’s lines and nail fold psoriasis, which are not included in this assessment tool, should be considered essential symptoms for indicating the activity of nail psoriasis. Although NAPSI is the most widely used tool for assessing the severity of nail psoriasis, it has uncontrolled limitations. Although other assessment tools have been developed, none have successfully replaced the NAPSI. In clinical trials for nail psoriasis, the NAPSI is used in various forms, such as improvement rates, changes in the mean NAPSI score, and achievement rates of NAPSI 75. Consequently, caution is warranted when interpreting the clinical trial results related to nail psoriasis improvement.

show abstract

Section: Application Of Nail Psoriasis Severity Assessment Tools For ...mentioning

confidence: 99%

Section: Application Of Nail Psoriasis Severity Assessment Tools For ...mentioning

confidence: 99%

Nail Psoriasis: Clinical Features and Severity Assessment

Youn

2024

Ann Dermatol

View full text Add to dashboard Cite

show abstract

“…In terms of systemic agents used to treat nail psoriasis, most data recorded to date are on adalimumab [23][24][25][26][27], which is also the only biologic therapy with efficacy data cited in the US Food and Drug Administration's package insert [28]. However, multiple other biologic and systemic therapies have been studied in the treatment of nail psoriasis, including apremilast [29][30][31][32], certolizumab [33,34], etanercept [35][36][37], infliximab [35,38,39], guselkumab [40], ixekizumab [41][42][43][44][45], secukinumab [34,[46][47][48], ustekinumab [49][50][51], acitretin, [52] methotrexate [53,54], cyclosporine [53], brodalumab [55,56], golimumab [57], and tofacitinib [58,59]. Results of studies evaluating the efficacy of systemic agents in treating nail psoriasis are summarized in Table 1.…”

Section: Systemic Therapiesmentioning

confidence: 99%

Nail Psoriasis: A Review of Effective Therapies and Recommendations for Management

Hadeler

Mosca

Hong

et al. 2021

Dermatol Ther (Heidelb)

View full text Add to dashboard Cite

Nail psoriasis has a prevalence that ranges from 10 to 82% and can significantly impact the quality of life of patients. Nail psoriasis is one of the most challenging areas to treat, and multiple therapies have been explored. Topical and injectable therapies are recommended for fewnail disease. Systemic therapies, including biologics, can be considered for patients with multiple and resistant nail disease, impaired quality of life, and severe skin and joint involvement, due to their long-term efficacy. Although outcome data are difficult to compare, interleukin (IL)-17 inhibitors may have superior short-term efficacy when compared to IL-23 inhibitors and tumor necrosis factor (TNF)-alpha inhibitors, although long-term efficacy is similar to TNF-alpha inhibitors. IL-23 inhibitors and TNF-alpha inhibitors have a similar efficacy for nail psoriasis.

show abstract

Latest Research in Nail Psoriasis

Pasch

Iorizzo

2021

Advances in Nail Disease and Management

View full text Add to dashboard Cite

Determination of the Nail Psoriasis Severity Index improvement rate standards for nail psoriasis treatment in a phase IV clinical trial of ustekinumab: the MARCOPOLO study

Cited by 6 publications

References 7 publications

Nail Psoriasis: Clinical Features and Severity Assessment

Nail Psoriasis: Clinical Features and Severity Assessment

Nail Psoriasis: A Review of Effective Therapies and Recommendations for Management

Latest Research in Nail Psoriasis

Contact Info

Product

Resources

About